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Summary 
A  cytolytic T  lymphocyte (CTL) clone that lyses many HLA-A2 melanomas was derived from 
a  population  of tumor-infiltrating  lymphocytes of an  HLA-A2 melanoma  patient.  The gene 
coding for the  antigen recognized by this  CTL was identified by transfection of a  cDNA li- 
brary.  It is  the  gene which has been reported  to code for N-acetylglucosaminyltransferase V 
(GnT-V). Remarkably, the antigenic peptide recognized by the CTL is encoded by a sequence 
located in an intron.  In contrast to the  fully spliced  GnT-V mRNA,  which was  found in a 
wide range of normal and tumoral tissues,  the mRNA  containing the intron region coding for 
the antigen was not found at a significant level in normal tissues.  This mRNA was observed to 
be present in about  50% of melanomas.  Our results  suggest that a promoter located near the 
end  of the  relevant  intron  is  activated  in  melanoma  cells,  resulting  in  the  production  of an 
mRNA  coding for the antigen. 
C 
Ytolytic T  lymphocytes (CTL) directed against human 
tumor cells  have been obtained by culture  of irradi- 
ated  tumor  cells  with  autologous  blood  lymphocytes,  or 
with tumor infiltrating lymphocytes (reviewed in reference 
1).  From  these  responder  T  cell  populations,  it  has  been 
possible to derive stable anti-tumor CTL clones that do not 
lyse autologous fibroblasts,  EBV-transformed autologous B 
cells,  or target cells that are lysed by NK-like effectors (2-6). 
Two main categories of antigens recognized on human 
melanomas by autologous CTL have been described so far. 
Some antigens are encoded by genes that are expressed in a 
wide range of tumors of different histological types but not 
in normal tissues except in testis and placenta. Examples are 
the MAGE gene family (7, 8), the BAGE gene (9), and the 
GAGE gene family (10). Others are differentiation antigens 
encoded by genes  that  are  expressed  only in  melanocytes 
and  in  melanomas,  such  as  those  encoded  by  tyrosinase 
(11-14)  and  those  encoded  by  Melan-A  ~a~T-I  (15,  16) 
gpl0O  Pme117 (17,  18), and gp75  Tp'PI (19). 
We report here the identification of another gene coding 
for  a  melanoma  antigen,  which  is  recognized  by  a  CTL 
clone on a majority of HLA-A2 melanomas. The antigenic 
peptide which binds to HLA-A2.1 is encoded by an intron 
sequence of the gene that codes for N-acetylglucosaminyl- 
transferase V. 
Material and Methods 
Cell Lines.  Tumor  ceU  lines  NA8-MEL,  NA17-MEL,  and 
NA74-MEL were derived from the metastatic  melanomas of pa- 
tients NA8, NA17, and NA74. Cell line MZ2-MEL is a subclone 
of the original MZ2-MEL melanoma line, and was described pre- 
viously as MZ2-MEL.43 (5, 20). This subclone expresses tyrosi- 
nase. Subline  MZ2-MEL.2.2.5, used for construction of the ge- 
nomic library,  was derived as described (10). Melanoma cell fines 
SK29-MEL and SY,  L23-MEL, and RNA extracted from cultivated 
melanocytes were gifts from Dr. L. Old (Memorial Sloan-Ketter- 
ing Cancer Center,  New York).  Tumor cell fines LB373-MEL 
and LB168-MEL were derived from melanoma patients  LB373 
and LB168 respectively.  Tumor cell lines MI10221 and 526-mel 
were kindly provided by Dr. G. Parmiani (Istituto  Nazionale Tu- 
moil, Milan,  Italy) and Dr. S.A. Rosenberg (National Cancer In- 
stitute, Bethesda, MD), respectively. CTL clone NA17-CTL-213, 
referred to as CTL 213, was derived from TIL of patient NA17 
(6). Lymphoblastoid cells NA17-EBV were derived from patient 
NA17 by standard techniques. 
Assay for Cytolytic Activity.  The  chromium  release  assay was 
performed as described  elsewhere  (5). Briefly,  1,000 51Cr-labeled 
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to-target ratios.  Chromium release in the supernatant was mea- 
sured after 4 h of incubation. 
Construction of the eDNA Library.  Poly-A*(RNA) was obtained 
from MZ2-MEL  cells using the  Fastrack mRNA extraction kit 
([nvitrogen Corporation, Oxon, UK). mRNA was converted to 
cDNA using an oligo-dT(Notl, EcoRl) primer. The cDNA was 
ligated to  BstXl  adaptors,  digested with  NotI  and inserted into 
the BstXl and Notl sites of expression vector pcDNAI/Amp (In- 
vitrogen Corporation, Oxon, UK). Recombinant plasnfids were 
electroporated  into  DH5~x  Escherichia coil bacteria  and  selected 
with ampicillin (50 p~g/ml). Bacteria were amplified to saturation 
and plasnfid DNA was extracted by the alkahne lysis method (21). 
Transfection of COS-7 Cells.  Transfection  experiments  were 
performed by the  DEAE-dextran-chloroquine method  (11,  15, 
22).  Briefly 1.5  ￿  104 COS-7 cells were  treated with  100 ng of 
plasmid  pcDNAI/Amp-A2,  a  recombinant plasmid  containing 
the HLA-A2.1 gene isolated from a CTL clone of patient SK29 
(23),  and 100 ng ofDNA of a pool of the cDNA library. Trans- 
fected COS-7 cells  were  tested in a CTL stimulation assay after 
48 h. 
CTL Stimulation Assay.  Transfectants  were  tested  for  their 
ability to  stimulate  the  production  of Tumor  Necrosis  Factor 
(TNF)  by  CTL  (24).  Briefly,  in  microwells  containing target 
cells,  2,500 CTL were added in 100 ILl of RPMI  1640 medium 
(Gibco BRL,  Gaithersburg, MD)  containing 10% human serum 
and 25 U/ml r-hu-lL2. After 48 h, the supernatant was collected 
and its TNF content was determined by testing its cytotoxic ef- 
fect on WEHI-164 clone 13 cells (25) in a MTT colorimetric as- 
say (24, 26). 
DNA Sequencing and Homology Search.  DNA sequencing analy- 
sis was performed by specific priming with synthetic oligonucle- 
otides. The sequencing reactions were performed by the dideoxy- 
chain termination method (T7 Sequencing Kit; Pharmacia, Uppsala, 
Sweden, ATaq  TM  Cycle-Sequencing Kit; USB, Cleveland, OH). 
The computer search for sequence homology was done with the 
blast program. 
Production of Fragments of cDNA  560 
Prqc~ressive Deletions in eDNA 560.  The  plasmid  was  opened 
with NotI and SphI before digestion with exonuclease III. This 
treatment was performed with the Erase-a-base System (Promega, 
Madison, WI). After ligation, the plasmids were electroporated in 
TOP  10F'  E.  coli bacteria and selected with ampicillin (50  ~g/ 
ml). Clones were isolated, plasmid DNA was extracted from each 
clone and transfected into COS-7 cells  together with the HLA- 
A2.1 gene. 
PCR Fragments of cDNA 560.  Fragments were generated from 
cDNA  clone  560  by  PCR  amplification. They were  blunted, 
phosphorylated and subcloned in vector pcDNAl/Amp digested 
by EcoRV. To generate PCR fragment 47-185,  we used VB45 
(5'-GATGTGTTCATACGCTGTGTGGT-3') as sense primer, 
and VB56  (5'-TCAGCTTTTGGGTGGGTTGAACTTGG-3') 
as anti-sense primer. To generate PCR fragment 35-82, we used 
as sense primer VB72 (5'-GCCGCCATGGTCCTGCCTGAT- 
GTG-Y) which generates an ATG (underlined) that has  the ap- 
propriate Kozak consensus sequence, and YG15  (5'-CTAGTG- 
TAAGACAGAAAACCACACAGCGTATGAA-3')  as anti-sense 
primer. 
Screening of the Genomic Library.  A  genomic library of 1.1  ￿ 
106  independent  X  phages  was  constructed  with  DNA  from 
MZ2-MEL2.2.5  by standard techniques  (21).  A  labeled cDNA 
560 fragment (nt 47  to  185)  was used as a  probe  (probe B)  for 
colony hybridization. A positive phage was isolated and digested 
with Sacl. The fragments were size-fractionated in a 0.7% agarose 
gel and blotted on a nitrocellulose filter. The filter was hybridized 
with probe  A,  a 33p-labeled oligonucleotide (5'-GGTTTCTC- 
GAAGAAGGAACTGC-3') specific  of exon  "'A"  of  GnT-V 
cDNA (positions 1651  to  1672).  5.5- and 8.5-kb fragments, hy- 
bridizing with probe A and probe B, respectively, were then sub- 
cloned in plasmid pTZ19R  (Pharmacia  Fine Chemicals,  Pisca- 
taway, NJ) and partially sequenced. 
mRNA Analysis.  Anchored PCR amplifications of 5' and 3' 
ends of the cDNA coding for NA17-A antigen were performed. 
cDNA  was  synthesized using total  RNA  from  HLA-A2  mela- 
noma cell line LB24-MEL as template. 
5" End Amplification.  5' end amplification was performed us- 
ing the 5'-Amplifinder  TM  RACE Kit (Clontech, Palo Alto, CA). 
Positions of primers are  indicated in figure 7.  Primers  used for 
cDNA  synthesis  were  YG104  (5'-CAGCGTATGAACACA- 
TCAGGC-3')  or  VB56  (5'-CTTTTGGGTGGGTTGAACT- 
TGG-3').  cDNA  was  ligated  to  Amplifinder  TM  anchor  as  de- 
scribed in the kit. A first  round of PCR amplification was done 
with  anti-sense  primers  YG104  or  YG20  (5'-AGGACCAT- 
CAGGCAGGAC-Y) and sense  Amplifinder anchor primer.  A 
second round of amplification was realized with anti-sense prim- 
ers  YG20  or  YG31  (5'-CACTATGCTCTCCTCCACCAAG- 
3') and the sense Amplifinder anchor primer. Amplified products 
were  cloned  in  vector  pCR-Script  TM  SK(+)  (pCR-Script  TM 
SK(+) Cloning Kit; Stratagene, LaJolla, CA) and sequenced. 
31End Amplification.  The  primer  used  for  cDNA  synthesis 
was  EDP1260  (5'-GACTCGAGTCGACATCGATTTTTT- 
TTTTTTTTTTT-3', described by Frohman [27]).  A first PCR 
amplification was done with sense primer VB72 (5'-ATGGTC- 
CTGCCTGATGTG-3')  and  anti-sense  primer  EDP1260.  A 
second  PCR  amplification was  done  with  sense  primer  VB45 
(5'-GATGTGTTCATACGCTGTGTGGT-3') and  anti-sense 
primer EDP1260. The amplified product was cloned as above. 
In  Vitro Transcription Assay.  The  1389-bp  Hindlll-Sacl  re- 
striction fragment of the 8.5-kb genomic subclone was inserted in 
transcription vector pGEM3Zf(-) (Promega, Madison, WI). 1 gtg 
Sacl-digested plasmid was diluted to a final volume of 50 I.tl with 
10 b~l 5X SP6 buffer (GIBCO BRL), 5/.H each NTP at 10 raM, 
2.5  btl  dithiotreitol  at  0.1  M,  2  p~l  (20U)  RNase  inhibitor 
(GIBCO BRL) and 3  IM (45U)  SP6 RNA polymerase (GIBCO 
BRL).  This mixture was  incubated at 37~  for 2  h.  I  ptl  (1U) 
RQ1  DNase  (Promega)  was  added  and the  mixture was  incu- 
bated again for 45 rain at 37~  RNA was ethanol precipitated, 
resuspended at a final concentration of 2  Ixg/btl and serially di- 
luted in 2 Ixg/txl yeast tRNA (Boehringer Mannheim Corp., In- 
dianapolis, IN). 1 ILl of 10 .2 and 10 .4 RNA dilutions was reverse 
transcribed as  described in the  RT-PCR  assays section,  except 
that YG104 or VB56 primers (4 ~xl at  10 ~M) were used instead 
of an oligo-(dT-15) primer. To exclude contamination with plas- 
mid DNA,  control reactions were  included where  no MoMLV 
reverse  transcriptase was  added.  1/40 of the  completed  reactions 
were  engaged in 30  PCR  cycles  with YGl18  (5'-AGGGGA- 
AAATCAACACCAAGATG-3') as  sense primer and YG20  as 
anti-sense primer. PCR products were fractionated by agarose gel 
electrophoresis. Control reactions yielded no detectable product. 
Antigenic Peptides and CTL Assay.  Peptides  were  synthesized 
on solid phase  using F-moc for transient NH2-terminal protec- 
tion as described (28) and characterized by mass spectrometry. All 
peptides were >90% pure as indicated by analytical HPLC. Lyo- 
philized peptides were dissolved in DMSO and stored at -80~ 
They were  tested  by chromium release  assay as  previously de- 
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SlCr-labeled for one hour at 37~  and washed extensively. 1,000 
target cells were  then  incubated in  96-well microplates in  the 
presence of various concentrations ofpeptides for 30 min at 37~ 
and CTL 213  (10,000 cells) were added. Chromium release was 
measured after 4 h at 37~ 
RT-PCR Assays.  Total  RNA  was  extracted by  the  guani- 
dine-isothiocyanate procedure  as  described (30).  Reverse  tran- 
scription was performed on 2 Ixg of total RNA in a reaction vol- 
ume  of 20  Ixl  with  4  ILl  of 5￿  reverse  transcriptase  buffer 
(GIBCO  BILL),  2  p,1  of a  20  mM  solution  of oligo(dT-15) 
primer, 4 ~1 ofdNTPs at 2.5mM each, 20 U ofRNasin (Promega), 
2  Izl of 0.1  M  dithiotreitol and 200 U  of MoMLV reverse tran- 
scriptase (GIBCO BRL). The reaction was incubated at 42~  for 
60 min. 
For PCI~, ~0 of the cDNA reaction was supplemented with 
2.5 ILl of 10￿  thermostable DNA polymerase buffer (Finnzymes 
OY, Expoo, Finland), 0.5 ~1 each of 10 mM solution ofdNTP, 
0.625  ~1  each  of 20  b~M  solution  of primers,  0.5  U  of Dy- 
naZyme  TM  (Finnzymes OY) and water to a final volume of 25 I-d. 
For amplification of NA17-A cDNA  (PCtk "I-C"), VB45  was 
used as sense primer (primer i) and  (5'-CTCTACTTCCTCC- 
TGATTGTTGAG-3') as anti-sense primer (primer c). For am- 
plification of GnT-V cDNA (PCR "A-B"), primer a (5'-GAT- 
CTACTTGGACATTATTCACAC-3') was used as sense primer 
and primer b  (5'-CATCCATTTGCGATAGCTTCCAG-3') as 
anti-sense primer.  For amplification of cDNA  560,  VB45  was 
used as sense primer, and SL6 (5'-CAATGTCGGTCTTTTCT- 
GTC-3') as anti-sense primer. The ability ofoligonucleotide SL6 
to  prime  DNA  synthesis  in  presence  of template  cDNA  was 
tested  with  sense  primer SL5  (5'-GAAGAAGAGCAGGTCA- 
GCAGTC-3'), located in positions 345  to  366  of cDNA 560. 
This control reaction yielded specific amplification products with 
several tumoral R.NAs. 
PCR. were performed for 30 cycles (1  rain at 94~  2 rain at 
62~  and 2 min at 72~  10 ~1 of the PCR product were frac- 
tionated on a 1.5% agarose gel. The quality of RNA preparations 
was checked by PCtk amplification of ~-actin cDNA with prim- 
ers  (5'-GGCATCGTGATGGACTCCG-3')  and  (5'-GTCG- 
GAAGGTGGACAGCGA-3') for 21  cycles of 1 rain at 94~ 
2 rain at 65  ~ and 2  min at 72~  PCR  assays for tyrosinase ex- 
pression were performed as described (11),  except that the num- 
ber of cycles varied between 30 and 38 cycles. 
For quantitative expression measurements, cDNA was synthe- 
sized as above.  R.NA obtained from MZ2-MEL cells was used 
undiluted or serially diluted in E. coli tRNA for each series of  quan- 
titative PCR.  0.2  ~xCi of labeled dCTP  (3,000  Ci/mmol) were 
added to the PCR mix. The number of cycles was reduced to 24 
for PCtk I-C, to 25 for PCP,. A-B and to 18 for ~-actin PCR so 
that a linear dilution curve of the standard was obtained. Accurate 
quantitation was obtained using the phosphor-imager technology 
(Phosphor-Imager; Molecular Dynamics, Sunnyvale, CA). 
Results 
An  Anti-melanoma  CTL  clone Restricted  by  HLA-A2. I. 
Melanoma cell line NA17-MEL was estabhshed from a cu- 
taneous metastasis of patient NA17. Anti-tumor CTL were 
obtained from tumor-infiltrating lymphocytes by culturing 
fragments of a metastasis in presence of IL-2 (6). This CTL 
population  was  restimulated  with  irradiated  NA17-MEL 
cells  under  limiting  dilution  conditions,  and  stable  anti- 
tumor CTL clones were obtained (6). 
CTL clone NA17-CTL-213,  further referred to as CTL 
213, lysed the autologous melanoma cell line but lysed nei- 
ther  K562  nor  autologous EBV-transformed B  cells  (Fig. 
1).  The  target  antigen  of this  CTL  was  named  NA17-A. 
CTL clone 213 lysed 12 other melanoma cell lines carrying 
the  HLA-A2  haplotype  among  the  15  that  were  tested, 
suggesting that antigen NA17-A is presented by HLA-A2 
(31).  It also produced TNF in the presence of NA17-MEL 
and other HLA-A2 melanoma cell lines (Fig. 2). 
The  lysis  inhibition  observed  with  two  distinct  anti- 
HLA-A2 monoclonal antibodies confirmed  that  HLA-A2 
was the presenting molecule for the antigen recognized by 
CTL 213  (31).  This was confirmed further by transfection 
of the  HLA-A2.1  gene  into  melanoma  line  MZ2-MEL, 
which does not carry the HLA-A2 gene. The acquisition of 
the HLA-A2.1  sequence rendered this cell line capable of 
stimulating TNF release by CTL 213  (Fig. 2). 
A  cDNA Coding for Antigen NA 17oA.  A  cDNA  library 
was  constructed in expression vector pcDNAI/Amp  with 
poly A +  (RNA)  extracted from MZ2-MEL  cells. The  li- 
brary was divided into 640 pools containing each '~90 bac- 
teria  carrying an  insert.  Plasmid DNA  of each  pool  was 
cotransfected  into  COS-7  cells  with  plasmid  pcDNAI/ 
Amp-A2,  containing the  HLA-A2.1  gene.  Duplicate mi- 
crocultures were transfected and screened two days later for 
their  ability to  stimulate  TNF  release by  CTL  213.  The 
DNA  of one of the 640 pools produced in both duplicates 
a level of TNF that was significantly above the average and 
this  was  confirmed  in  a  second  transfection  experiment. 
Bacteria of the positive pool were cloned and their plasmid 
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Figure 1.  Cytolytic activity of CTL clone 213 on cells of the autolo- 
gous melanoma line (NA 17-MEL), on autologous EBV-transformed B 
cells (NA 17-EBV), and on K562 cells. Target cells were chromium la- 
beled and incubated with the CTL at different effector-to-target (E/T) 
ratios. Chromium release was measured after 4 h, 
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MEL and of other HLA-A2 melanoma cell lines NA74-MEL, SK23- 
MEL, and LB373-MEL. Melanoma cell line MZ2-MEL does not carry 
HLA-A2. MZ2-MEL.HLA-A2.1 is  a MZ2-MEL subclone transfected 
with  a HLA-A2.1 gene. 2,500 CTL were added to  10,000 melanoma 
cells, and the TNF content of the supernatant was tested after 24 h on 
WEHI-13 cells. 
DNA was  cotransfected with  the  HLA-A2.1  construct  as 
before. Two out of 1,150 clones stimulated TNF release by 
CTL 213.  The  result  obtained with  one  of these,  namely 
cDNA clone 560, is shown in Fig. 3. 
The sequence ofcDNA 560 proved to be 2,237 bp long. 
By searching GenBank,  we found that nucleotides  (nt)  84 
to 230 were identical  to a  region  of a  cDNA reported by 
Saito  and  coworkers  to  code  for  N-acetylglucosaminyl- 
transferase V  (GnT-V) 1 (32).  The sequence upstream of nt 
84 and that downstream of 230 showed no significant ho- 
mology with any sequence recorded in databanks. 
The cDNA library derived from the MZ2-MEL cell line 
was searched for sequences related to cDNA 560 by colony 
hybridization. Using as a probe a XbaI restriction fragment 
of cDNA 560  extending from position  1  to  973  (Fig.  4), 
we  identified  several  clones  (not shown  in  Fig.  4)  which 
differed  completely  from  cDNA  560  up  to  position  230 
but were completely identical after this position. The com- 
position of cDNA 560 appeared therefore to be particularly 
complex with  a  central fragment  (84-230)  identical  to the 
GnT-V cDNA (Fig. 4, region B)  and two completely un- 
related  terminal  fragments.  This  raised  the  possibility  that 
cDNA 560 was an artefactual ligation product of unrelated 
cDNAs.  RT-PCR  experiments  carried  out  with  MZ2- 
MEL RNA and involving a sense primer in positions 47 to 
69 (VB45) and an anti-sense primer in positions 608 to 628 
(SL6)  failed to yield an  amplified product,  consistent with 
the notion that, in cDNA 560, at least two fragments were 
artefactually combined. 
1Abbreviations used in this paper: GnT-V, N-acetylglucosaminyltransferase 
V; lkT, reverse transcription. 
Figure 3.  Stimulation of CTL 213 by COS-7 cells cotransfected  with 
HLA-A2.1 and cDNA 560 cloned in pcDNAI/Amp.  CTL were added 
1 d after the transfection and the TNF content of the supematant was es- 
timated 1 d later by testing its toxicity of  WEHI-13 cells. 
Identification  of the Antigenic Peptide.  To  identify  the  se- 
quence  coding  for  the  antigenic  peptide  recognized  by 
CTL 213, we produced progressive deletions of the 3' end 
of cDNA clone 560 with  exonuclease  III. By cotransfect- 
ing  the  truncated  clones  into  COS-7  cells  together  with 
the HLA-A2.1 construct, we found that the region ranging 
from  nt  1  to  291  transferred  the  expression  of antigen 
NA17-A (Fig.  5).  Using PCk  amphfied fragments cloned 
in expression vector pcDNAI/Amp, we identified a 48-bp 
fragment (nt 35 to 82) that transferred the expression of the 
antigen  (Fig.  5).  Another  amplified  sequence  extending 
from nt 47 to  185 proved unable to transfer the expression 
of NA17-A.  We  concluded  that  the  starting  point  of the 
sequence  coding for the antigenic  peptide  was located be- 
tween nt 35 and 47. We observed that nt 38-67 coded for a 
decapeptide  corresponding  to  the  consensus  sequence  of 
the  peptides  binding  to  HLA-A2.1  (33).  This  peptide, 
VLPDVFIRCV,  was  synthesized  and  incubated  with  T2 
cells,  which  are  HLA-A2 cells with  an  antigen processing 
defect resulting in an increased  capacity to present  exoge- 
nous peptides  (34, 35). T2 cells incubated with the peptide 
were lysed by CTL 213. Nonapeptide VLPDVFIRC sensi- 
tized  T2  cells  equally  well,  with  half-maximum  lysis  ob- 
tained  at peptide  concentrations  of 1  nM,  whereas  nona- 
peptide  LPDVFIRCV and octapeptide  VLPDVFIR failed 
to confer recognition by the CTL (Fig. 6). 
Antigen NA 17-A Is Encoded  by an Intron.  The coding se- 
quence of the antigenic peptide was located on cDNA 560 
in  front  of  the  region  corresponding  to  the  published 
GnT-V cDNA (Fig. 4).  Accordingly, it seemed that either 
this  sequence belonged to an unrelated  cDNA which had 
been  ligated  in  front  of the  GnT-V  sequence,  or  it  be- 
longed to the  GnT-V gene,  as part of an alternative  exon 
or an unspliced  intron.  To  explore  the  second possibility, 
we set out to isolate the GnT-V gene. 
A  h  gene hbrary prepared with DNA of the MZ2-MEL 
cell line  was  screened  with  probe B,  corresponding to  nt 
1176  A Human Tumor Antigen Encoded by the N-acetylglucosaminyltransferase V Gene Figure 4.  Comparison  of cDNA 560, of the GnT-V cDNA reported by Saito et al. (32) and of a genomic clone containing part of the GnT-V gene. 
The limits of  the 14-kb genomic fragment are indicated. The exons of  the GnT-V gene fragment are represented as full boxes. Most of the intron located 
between exons A and B (large stippled line) was not sequenced but its approximate  length could be evaluated from the length of restriction fragments. The 
right part (small stippled lines) of the representation  of the GnT-V gene is purely hypothetical.  Probes A and B used in hybridization  experiments  are indi- 
cated by bold lines. The arrows noted a, b, i, and c represent the locations of the primers used for R.T-PCR as described in the text. 
47-185  of cDNA  560  (Fig.  4).  A  positive  clone  with  a 
14-kb insert was identified. The digestion of this insert with 
SacI  produced  two  fragments  of 8.5  and  5.5  kb,  respec- 
tively. The first hybridized with probe B. The 5.5-kb  frag- 
ment hybridized with an ohgonucleotide  (Fig. 4,  probe A) 
corresponding to a sequence of the reported GnT-V  cDNA 
(32)  located  a  few nucleotides  upstream  of the  region  03) 
shared  with  cDNA  clone  560.  Thus  it  appeared  that  the 
Figure 5.  Identification  of the region coding for the antigenic peptide recognized by CTL 213. The limits of the exonuclease products and PCR frag- 
ments that were cloned into pcDNAI/Amp and transfected into COS-7 cells together with the HLA-A2.1  gene are indicated. Transfected cells (30,000' 
were incubated for 24 h with 2,500 CTL and the TNF in the supernatant was measured by its toxicity on WEHI-13 cells. 
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Figure 6.  Lysis  by CTL 213 ofT2 cells, which express HLA-A2, after 
incubation with synthetic peptides corresponding to sequences of cDNA 
560. Target cells were chromium labeled and incubated for 30 min with 
the peptides at the concentrations indicated. CTL 213 was then added at 
an E/T ratio of 10. Chromium release was measured after 4 h. 
8.5-kb  genomic fragment contained  the  GnT-V exon  (B) 
shared with cDNA 560, whereas the 5.5-kb fragment con- 
tained the preceding GnT-V exon (A). 
Partial sequencing of the 8.5-kb fragment (Fig. 7) showed 
that it  contained  a  sequence  identical  to  exon B  and,  im- 
mediately in front  of it,  a  sequence  identical  to the  initial 
84  bp  of cDNA  560,  which  contain  the  sequence  coding 
for the antigenic peptide.  This region ends with a consen- 
sus splice acceptor sequence.  Downstream of region B, the 
sequence  of the  8.5-kb  genomic  fragment  corresponded 
neither  to  that  of cDNA  560,  nor to  that  of the  GnT-V 
cDNA.  The two first nucleotides  of this sequence are GT, 
as expected for the beginning of an intron. 
In the  5.5-kb  SacI fragment of the  genomic  clone  (Fig. 
7) we found a sequence identical to the  150 bp sequence of 
the  GnT-V cDNA  (positions  1526  to  1675)  that immedi- 
ately precedes region B. This exon (A) is preceded and fol- 
lowed by consensus splice sites. 
We conclude that the genomic clone contains two exons 
(A and B)  which  are present in the  GnT-V cDNA.  They 
are separated by an intron of at least 8  kb (Fig. 4).  The se- 
quence  coding for the antigenic peptide is located near the 
very end  of this  intron.  Its phase  is  different  from that  of 
the  large  open  reading  frame  which  runs  through  all  the 
GnT-V cDNA. 
Characterization of the mRNA  Coding  for Antigen NA 17-A. 
The  intron  region  coding for the  antigenic  peptide  could 
be available for translation as a result of the presence of in- 
completely spliced Gnt-V messenger in the cytosol. Alter- 
natively,  a  normally silent promoter  region  located  in  the 
intron  between  exons A  and B  (Fig.  4)  could be activated 
in some melanoma cells to produce  an additional  messen- 
ger species. In the first hypothesis, 5' anchored PCR would 
be expected to yield long and diverse products correspond- 
ing to incomplete  cDNA molecules,  since  the  intron  is at 
least 8  kb long.  In the  second hypothesis,  and in  so far as 
the relevant promoter would be located near the end of the 
intron,  complete 5'  anchored PCR  products could be ob- 
tained indicating the new transcription starting point. 
Three  independent  anchored  PCR  experiments  were 
performed  on  RNA  of melanoma  cell  line  LB24-MEL, 
which  is  highly  recognized  by  CTL  213  (Table  1).  The 
primers are shown in Fig.  7.  In experiment I, reverse tran- 
scription  (RT)  was  primed  with  oligonucleotide  YG104, 
located in the intron.  The cDNA was ligated to an anchor 
oligonucleotide  and submitted to two consecutive series of 
30  amplification  cycles  with  the  anchor  complementary 
primer  and  as  anti-sense  primers  the  reverse  transcription 
primer in the first series of amplification and primer YG20 
(Fig. 7) in the second. The three cloned PCR products that 
were sequenced started at positions -247,  -198 and -91 rel- 
ative to exon B  (Fig.  7, vertical arrows).  In experiments II 
(RT primer YG104,  second anti-sense YG31)  and III (RT 
primer  VB56,  second  anti-sense  YG20),  PCR  products 
with  5'  ends scattered between  -288  and  -96  were identi- 
fied.  These  results  suggest  the  existence  of an  imprecise 
transcription  origin located in the distal part of the intron. 
To exclude  the  possibility of artefactual  anchored  PCR 
results due  to a secondary structure  in the RNA  molecule 
blocking reverse transcription,  we cloned in a transcription 
vector a HindlII-SacI restriction fragment containing exon 
B  and the last 1087  bases of the preceding intron  (Fig.  7). 
Sense  RNA  was  synthesized  in  vitro  and  reverse  tran- 
scribed  with  primer YG104.  PCR  was performed  on  the 
cDNA  product  with  anti-sense  primer  YG20  and  sense 
primer YGl18  which  starts  at  position  -588,  i.e.,  300  nt 
upstream of the earliest putative transcription starting point 
identified  by anchored  PCR.  A  specific  531-bp  band was 
obtained,  indicating  that  the  reverse  transcriptase  can  run 
across the putative transcription start region. 
To identify the  3'  end  of the  messenger containing  the 
peptide coding region, we used an oligo-dT primer for re- 
verse  transcription  of LB24-MEL  RNA.  The  cDNA  was 
then  submitted  to  two  series of PCR  amplification  cycles 
with  oligo-dT  primer  and  two  overlapping  sense  primers 
located in the peptide coding region.  The sequence  of the 
PCR  product  was identical  to  the  end  of the  intron,  fol- 
lowed  by the  complete  3'  end  (746  bp)  of the  published 
GnT-V cDNA.  It seems therefore that the  antigen coding 
messenger starts with  an  unusual  transcription  site located 
in an intron  but shows no further transcription  or splicing 
difference with the normal messenger.  In the antigen-cod- 
ing messenger,  the  open reading frame starts 49 bp before 
exon B  and it is interrupted  222 nt later, in the initial part 
of the putative exon "C" of the GnT-V gene. 
Expression of the Normal GnT-V Enzyme.  We  designed 
RT-PCR  assays that distinguish  the expression of the fully 
spliced  GnT-V  transcript  (32)  from  that  of the  transcript 
coding for antigen NA17-A. An RT-PCR  performed with 
primers located in exons A  and B  (Fig.  4; primers a and b) 
amplifies  a  206-bp  fragment  only  from  the  fully  spliced 
messenger. One sample of each of the large variety of nor- 
real adult tissues appearing in Table 3  was tested.  All were 
positive. So were all of 29 melanoma samples. 
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~exon A 
AGAAGTTCTAGTCCAGATACAGGTTGTTAT  GCAAATGAAAGAAAAAGAGAAAGTCTTGTGCTTGTTTTATTATTTAGAAT 
AAGAAGATCTACTTGGACATTATTCACACATACAT  GGAAGT  GCATGCAACTGTTTATGGCTC CAGCACAAAGAATA~CC 
CAGTTACGTGAAAAACCATGGTATC  CTCAGTGGAC  GGGACCTGCAGTTCCTTCTTCGAGAAACCAAGGTAAAAAT  T  CAC  C 
~on  A~ 
ACGGATGTGTTTCAGGT TATTGCCATTGC/2 TATGAAAATGGGATCAGAATATTTCATGC  TTGTTTTTCAAGTGCTGCAAT 
AAAC  TCTTGTGCTATTTT 
Partial sequence of the 8.5 kb fragment 
Hind III 
ATTGCTGTGAAAAGACCGAGGGAAAAACAGAACCAAGCTTGCAGCTAAATCTAGTTGAGCCATCTCCTTCATTCTCAACA  -1043 
CCT ~-4Z CTTGTGGT  TGGGTGATGCTCTGTGATGGCAGAAGGTAAC~ACGCC  CTGGC-~CC CAGTTATC  TTTTCTCACTTAA  -963 
TGTGCC  CCTGGGC~CTGAAACAGAACAGC42  TTTTATGT  GC~TAGAGAGGACACAGCT  TC  GTCAAGCC  CAGACCTGGAC  CC  -883 
TGC  CCATCAACAAC  CTGCAGTGCTCCAGCAGTGTGAAGTACACCCACTGTGATGGTACGTGCCGAGGCATTTCTGTGAGC -802 
AGT  TAT  TTC  ATTTT  TGGACCCAGGAAATCAGCACCACT  GAACTGCAGCTTGTCC  CCT TTGTCATCGTGC42  TTCCAGCT  GC  -723 
TGTGGTTGCTCTGAGGACTGAGAGCAAGTT  GTT  GC  TGC CATCTATGGTCTGTCTTGGGGGAAGCACATGGTTTGC  CTGCT  -645 
GGAGAGGGAAGCAGCTGCCTTGCAGAT  TCAGCAACACAC-CACC CTCTCTCCCCTCTGAGGGGAAAATCAACACCAAGATG  -563 
YGII8  / 
TTGGTGTCC CCAGTGTAAACCC CATTATGAAAACC TGT  GTTTACTGACCTACCATCATTTTAAAGCAGTTCCGTTTGAAC  -483 
TGC  AATCAAAC  CTC  CAAGTGAC  CTT  TCTGTCCC  TC  CGC  CCAGCATT  CCTGAAAGGCA~  CTGTTGTTTCTTTGGTTC AATGA  -403 
AGAAAC  CTTCTGTGTAGTTAAGCAAGT  GTTTTT  CCAGT  CATGTCTC  CTGGTGAGTTACAGAAGGATTATT  GTTGGGTC  TT  -323 
III  II  I 
GGT  GGT  GGTGGTGGTTGTTTTTCTTTTAATACT  CC~TC  CTC  CC  TAC  CCC  GTGAT~CC  CC  TAGACACTTAATTTTTTA~GTTC-243 
-288  -247  Ill  iII  I 
CTT  GGT  GGAGGAGAGCATAGTGAGTTGAGCAGC  TTTGT  GGGAC  TTTAAAAGTTC GTAGTTTTTCAGATCC TGGTGTAAGC  -163 
YG31  IX  -198  III  I  cDNA 560 
TGAATTCTCTCTGC CCCAC  CCC  CCAGGC-CCTGGGAC-CC TTC  CAAAGTGAGGTGT CCACACGGGAATGGC4~ CACAGAAT  CG  -83 
-96  -91 
I  V  L  P  D  V  F  I  R  C] 
,11 
YG20  I, Ill  YGI04  I, II 
~o~ B 
AGTTGTTT  GTTGGACTTGG GTTCCCTTACGAGGGCCCAGC  TCC  CCTGGAAGCTATC GCA/%ATGGATGTGCTTTTC TGAAT  +78 
I 
CCCAAGTTCAACCCACC CAAAAGCAGCAAAAACACAGACTTTTTCA~'~GGCAAGCCAAC  TCTGAGAGAGGTAAC-C AT  C  TA +158 
exon  B  ~ 
VB56  ZII 
TCAAAATTATT CCATTTTGAATAATATGAATAATAGCTATTTATTGAGTGCTCATGTAGGTATTAAC  CTTTCCATCTAAC  +238 
ATGATTGGGGGGGAGGGTGAGGGTATAGAGGCTCAGAGAGGCAAATGACCTGATCCTCGAGCTC  +302 
SacI 
Figure  7.  Sequences  sur- 
rounding  the  exons  present  in 
the  two  Sacl  restriction  frag- 
ments  of  the  14-kb  genomic 
insert.  Exons appear in bold, in- 
trons in plain text. The peptide- 
encoding sequence  also  appears 
in  bold.  It  is  immediately pre- 
ceded  by  a  start  codon 
(underlined). Nucleotides  of the 
8.5-kb  fragment  are  numbered 
from the first nt ofexon B. Posi- 
tions of primers used in  5'  an- 
chored PCR experiments are in- 
dicated  by  horizontal  arrows: 
bold  arrows  indicate  primers 
used  for  reverse  transcription, 
thin arrows those used for the fi- 
nal cycles of PCR amplification. 
Roman  numbers  below  each 
primer indicate in which experi- 
ment it was used. Vertical arrows 
represent  5'  extremities  of 
cloned anchored PCR products, 
and are noted I, II, or III to indi- 
cate  the experiment where they 
were obtained. Each arrow rep- 
resents one sequenced clone, ex- 
cept  for  arrow  noted  II  which 
represents  the extremity of eight 
different clones.  The vertical ar- 
row noted cDNA 560 shows the 
5' start  of cDNA 560.  Sacl and 
HindlIl restriction sites appear in 
italics.  These  sequence data  are 
available  from  EMBL/Gen- 
Bank/DDBJ  under  accession 
numbers X91652 and X91653. 
Expression  of  the  Antigen-coding  Sequence  in  Tumors. 
An  I<T-PCR  assay  named  I-C,  performed  with  a  sense 
primer  located  near  the  end  of the  intron  that  precedes 
exon B  and an anti-sense primer located downstream  exon 
B  in the GnT-V  transcript (Fig.  4, primers i  and c),  ampli- 
fies a 271-bp fragment only from the GnT-V  transcript that 
codes  for antigen  NA17-A.  This assay yielded  no  amplifi- 
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cation product with genomic  DNA,  indicating that the in- 
tron  located  between  exons  B  and  C  is  of  considerable 
length. 
13 HLA-A2  tumor  cell lines were tested with a  quantita- 
tive version  of RT-PCR  I-C  and also  for  their ability  to 
stimulate TNF  release by CTL  213  (Table 1). The  8  HLA- 
A2  tumor  cell  lines  that  stimulated  TNF  release  by  CTL Table  1.  TNF Assay and Quantitative  R T-PCR Results on  Table 2.  Expression  of NA 17-A in Tumor Samples 
HLA-A2  Tumor Cell Lines 
Expression of 
Recognition  the messenger 
HLA-A2  by CTL-213 in  coding for 
tumor cell fines  TNF assay*  antigen NA17-A* 
LB24-MEL  + + +  298% 
NA17-MEL  + +  175% 
MZ2-MEL.HLA-A2  + + +  100% 
(reference) 
NA74-MEL  + +  50% 
SK23-MEL  + +  32% 
LB373-MEL  +  30% 
526-MEL  +  19% 
MI15-MEL  +  14% 
LB168-MEL  +  8% 
LB96SAR.C  -  3% 
SK29-MEL  -  1% 
NA8~MEL  -  1% 
LB23-SA1<C  -  1% 
LB37-NSCLC  -  1% 
*The TNF assay was performed by adding 2,500 CTL 213 to 10,000 
tumor cells and testing the supematants 24 h later on WEHI-13 cells. 
*cDNA synthesis and 25 cycles of PCR I-C amplification were per- 
formed with trace amounts of [32P]dCTP as described in Materials and 
Methods. Results were quantitated on Phosphor-lmager and normal- 
ized according to the expression of ~-actin. Results are expressed as a 
percentage of the level of expression in melanoma line MZ2-MEL. 
213  had  a  level of expression of NA17-A messenger be- 
tween 300 and 8% of that observed in the MZ2-MEL celt 
line. There was a good correlation between the level of the 
NA17-A messenger and the  amount of TNF released by 
the  CTL.  The  five  HLA-A2  tumor  cell lines that  were 
negative in the  TNF  assay  expressed less  than 3%  of the 
amount of NA17-A messenger found in MZ2-MEL cells. 
42 melanoma samples and 198 samples of tumors other 
than melanoma were  tested by IkT-PCI< I-C  (Table 2). 
About  half  the  melanoma  samples  expressed  levels  of 
NA17-A messenger that should lead to antigen expression 
(More  than  12%  of that  of MZ2-MEL), while tumors of 
other types did not, with the exception of one brain tumor 
and one sarcoma. 
Expression  of the  Antigen-coding  Sequence  in  Normal  Tis- 
sues.  A  variety of normal tissue  samples  were  tested  by 
lkT-PCP, I-C for the  expression of the RNA  coding for 
antigen NA17-A (Table 3). All the 54 samples were nega- 
tive except for one breast sample (out of six tested) and one 
brain sample (out of five), which contained substantia ni- 
gra.  These samples gave signals evaluated to 3  and 4%, re- 
spectively, of the level observed in the MZ2-MEL cell line. 
Whereas  two  skin  samples  were  negative  in  the  IkT- 
Number of samples with 
a Na17-A Expression* 
Number of samples 
Type of tumor  tested*  >12.5%  2-12.5%  <2%9 
Adrenal gland  1  0  0  1 
Bladder  15  0  0  15 
Brain  10  1  2  7 
Breast  25  0  2  23 
Colon-rectum  10  0  4  6 
Head and neck  15  0  0  15 
Kidney  16  0  0  16 
Leukemia  8  0  3  5 
Lung  31  0  0  30 
Lymphoma  2  0  0  2 
Melanoma  42  20  9  13 
Neuroblastome  3  0  0  3 
Ovary  1  0  0  1 
Pancreas  4  0  1  3 
Prostate  14  0  0  14 
Sarcoma  22  1  2  19 
Skin  3  0  0  3 
Stomach  2  0  0  2 
Testis  11  0  0  11 
Thymus  1  0  0  1 
Thyroid  1  0  0  1 
Uterus  3  0  0  3 
*cDNA synthesis and 30 cycles of PCR I-C were performed as de- 
scribed in Materials and Methods. 
*Semi-quantitative  measurement was obtained by comparing ethidium 
bromide fluorescence of PCR products in samples to that in eighffold 
diluted MZ2-MEL.43 RNA (12.5%). 
~The limit of detection was evaluated to 2%. 
PCP, assay,  a melanocyte culture was clearly positive. We 
felt that the expression of the NA17-A messenger might be 
related to  in vitro  culture conditions and we  reexamined 
the  presence  of the  messenger in the  skin. We  evaluated 
the expression of the NA17-A coding sequence relative to 
that of the tyrosinase gene which is known to be expressed 
specifically  in  melanocytes.  We  considered  that  if  the 
NA17-A messenger is  produced  by  normal melanocytes, 
which constitute a few percent of the cells of the basal layer 
of the  epidermis,  the  expression of this  messenger in the 
skin sample ought to be decreased relative to that found in 
the  MZ2-MEL  melanoma line proportionately to  that  of 
the tyrosinase messenger. In the two skin samples that were 
tested we observed a level of tyrosinase mlLNA averaging 
7.5%  of that found in MZ2-MEL cells.  For the  NA17-A 
coding sequence the  average  was  only 0.45%,  suggesting 
that skin melanocytes do  not express a significant level of 
the sequence coding for antigen NA17-A. 
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Type of tissue 
Number of positive 
results/number of samples 
tested* 
Adrenal gland  0/3 
Bladder  0/4 
Brain  1/5 (4%)  5 
Breast  1/6 (3%)~ 
Cerebellum  0/I 
Colon  0/3 
Epididyme  0/2 
Heart  0 / 1 
Kidney  0/3 
Liver  0/3 
Lung  0/3 
Muscle  0/1 
Ovary  0/2 
Prostate  0/1 
Scar  0/2 
Skin  0/2 
Stomach  0/1 
Testis  0/3 
Thymocytes  0/1 
Uterus  0/1 
Placenta  0/1 
Foetal testis  0/1 
Foetal brain  0/3 
Umbilical cord  0/1 
*cDNA synthesis and 30 cycles of PCR I-C were performed as de- 
scribed in Materials and Methods. The percentage of NA17-A expres- 
sion compared to NA17-A expression in MZ2-MEL cell line was eval- 
uated in the two positive samples. 
~The brain sample was assayed by quantitative radioactive PCR as de- 
scribed. 
~The breast sample was evaluated by performing 38 PCR I-C cycles 
and comparing ethidium bromide fluorescence of  products to those ob- 
tained on serially diluted MZ2-MEL RNA. 
Discussion 
Tumor antigen  NA17-A is  expressed  by approximately 
50% of HLA-A2 melanomas. It is a product of the gene that 
codes for N-acetylglucosaminyltransferase V  (GriT-V).  This 
enzyme is located in the Golgi apparatus. It catalyzes the trans- 
fer of N-acetylglucosamine in [3(1,6)-linkage to the et(1,6)- 
linked  mannose  of biantennary  N-linked  oligosaccharides 
(35a). This enzyme is active in many normal tissues.  Its ac- 
tivity in many cell types has been shown to increase signifi- 
candy  after  infection  by  various  transforming  viruses  or 
transfection  with  oncogenes, such as  ras  (36-40).  For sev- 
eral cell lines,  increase in the activity of GnT-V appears to 
correlate with increase in the metastatic potential (41, 42). 
Remarkably,  the  region  coding  for  the  peptide  that 
binds to HLA-A2.1 to form antigen NA17-A is located in 
an intron. The results ofanchored-PCR amplification sug- 
gest  that  messengers  coding for the  antigenic  peptide  are 
generated  by  the  activation  in  melanoma  cells  of a  pro- 
moter located in this intron. No consensus TATA box can 
be found in the rather diffuse region where starting points 
of 5' anchored-PCR clones were found, and this may ac- 
count  for  the  absence  of a  precise  transcription  starting 
point.  The  examination  of the  putative  promoter  region 
did  not  reveal  any  transcription  factor  binding  sequence 
that seemed likely to be responsible  for the  transcriptional 
activation  in  melanoma.  We  intend  to  clone  this  region 
into a reporter vector, as a first step in analyzing the activa- 
tion of the putative intron promoter in the melanoma cells. 
The AUG codon, which immediately precedes the anti- 
gen coding sequence, does not benefit from a favorable up- 
stream sequence  for a translation  start:  instead  of the  con- 
sensus purine, there is a C  in position  -3.  But there is a G 
in position  + 4, which ought to compensate for this. 
The  decapeptide  VLPDVFIRCV,  which  is  recognized 
in  association  with  the  HLA-A2.1  molecule  by CTL  di- 
rected  against  NA17-A is a  consensus  HLA-A2.1  binding 
peptide  (33)  with  anchor residues  L  and V  in positions  2 
and  10,  respectively.  Interestingly,  nonapeptide  VLPDV- 
FIRC induces lysis by CTL 213 equally well, even though 
it lacks the COOH-terminal consensus anchor residue. 
The mRNA  that codes for the  NA17-A peptide  could 
also code for several other HLA-binding peptides  that are 
not  encoded  by the  normal  GnT-V  mRNA.  This  is  be- 
cause  the  AUG  located  in  front  of the  NA17-A peptide 
opens a reading frame which is out of phase with the nor- 
real  GnT-V  coding sequence  and  which  codes for a  poly- 
peptide  of 74  amino  acids.  Thus,  the  abnormal  GnT-V 
messenger  could  code  for  several  tumor  antigens  recog- 
nized by T  lymphocytes. 
We  examined  whether  antigen  NA17-A  is  a  melano- 
cytic differentiation  antigen like  those  encoded by tyrosi- 
nase, Melan-A  M~'r-l, gp 100  vr~e~7 and gp75, or whether its 
expression  is  restricted  to  tumors.  The  messenger  coding 
for antigen NA17-A seemed not to be expressed at a signif- 
icant level in the skin melanocytes, indicating that antigen 
NA17-A is not a differentiation antigen.  The expression of 
the NA17-A messenger appears to be tumor-specific, even 
though most normal tissues produced weak signals after 38 
PCR  cycles.  But  these  weak  signals  may result  from  the 
amplification of incompletely spliced but otherwise normal 
GnT-V messenger,  which is very unlikely to produce the 
antigenic peptide  since the peptide-coding sequence is lo- 
cated near the end of a very long intron containing multi- 
ple stop  codons in all  reading frames.  Even if these  weak 
signals represented the appropriate message, the level of ex- 
pression  would  most  probably  be  too  low  to  produce 
enough peptide  for CTL recognition. We conclude that it 
is very likely that the expression of antigen NA17-A is suf- 
ficiently tumor-specific to be a useful target for cancer im- 
munotherapy. 
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